Biotech Values

[DewDiligence]

Tysabri Resumes Modest Quarter-Over-Quarter Growth

The good news for BIIB and ELN is that Tysabri sales did not decline from quarter to quarter, as they did from 3Q08 to 4Q08 (#msg-35397974). The bad news for BIIB and ELN is that sales growth from 4Q08 to 1Q09 was almost non-existent in the US.

 
                         1Q09 4Q08 %Change 
 US sales ($M)            116  115  +0.9% 
 Ex-US sales ($M)         111  103  +7.8% 
 ===                     ==== ====  ===== 
 Worldwide sales ($M)     227  218  +4.1% 
  
 Thousands of patients   ==== ====  ===== 
 on Tysabri at qtr end*  39.4 37.0  +6.5%

*Excludes patients in clinical trials.

Source:
http://finance.yahoo.com/news/Biogen-Idec-Reports-First-bw-14949365.html